Nearly 26,000 women die from ovarian cancer each year in the European Union.
OvarianVax is a promising new vaccine in development that aims to train the immune system to recognize and attack the earliest stages of ovarian cancer. Researchers have secured £600,000 (€719,960) in funding, which will support laboratory research for the next three years, according to the University of Oxford.
“OvarianVax could provide a preventive solution, initially for women at high risk, and potentially on a larger scale if trials prove successful,” said Dr. Ahmed Ahmed, an Oxford gynecological oncologist and the lead of the OvarianVax project.
In the coming years, additional vaccines for other types of cancer may also become available. According to Euronews, Oxford scientists are working on a vaccine for lung cancer, and the HPV vaccine could significantly reduce cases of cervical cancer in the future.
